云顶国际

The CAR-T cell therapy is a gene engineering technology. It first transforms a fragment of scFv, an antibody capable of recognizing a tumor-specific antigen, then integrates the fragment into the transmembrane chain segment consisting of a series of molecules involved in T cell activation such as CD28, 4-1BB and CD3-ζ, forming a recombinant plasmid CAR. The CAR will be transduced into the T cells of a patient and cause them to express CAR. After the “re-coding”, a large amount of tumor-specific CAR-T cells will be generated to attack and eventually ablate the tumor.

Chimeric antigen receptor NK (CAR-NK) cell therapy is a gene engineering technology. It first transforms a fragment of scFv, an antibody capable of recognizing a specific tumor antigen and then integrates the fragment into the transmembrane chain segment composed of different combinations of molecules such as CD3-ζ, CD137, NKG2D and DAP10, forming a forming a recombinant plasmid CAR. The CAR will be transduced into the NK cells (from patients or healthy donors) and cause them to express CAR. After the “re-coding”, a large amount of tumor-specific CAR-NK cells will be generated to attack and eventually ablate the tumor.

More product columns are under construction, and treatment research will be carried out one by one in the future to benefit patients.